Brain wave study tests new drug for fragile x syndrome
NCT ID NCT06334419
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a single dose of gaboxadol affects brain activity in adult males with Fragile X syndrome. Ten participants aged 18 to 40 took either the drug or a placebo during home and clinic visits. The main goal was to measure changes in brain waves using EEG, not to treat symptoms. The study also checked if doing research at home is practical for this group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRAGILE X SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A common antidepressant may tame anxiety in kids with autism and ADHD — a trial puts it to the test
- Can early parent coaching help infants with rare genetic disorders thrive?
- Experimental drug aims to boost brain function in fragile x syndrome
- Newborn screening study aims to catch rare diseases at birth
- New drug trial aims to ease fragile x symptoms in men
- New drug shows promise for fragile x symptoms in small trial